TITLE:
Effect of Sacubitril-Valsartan Combined with Zhenyuan Capsule in the Treatment of Chronic Heart Failure Comorbid Anxiety and Depression and Its Effect on Inflammatory Factors
AUTHORS:
Jianhong Qin, Wenzhi Mo, Lixin Xie, Erneng Zhou, Guijiao Li, Rongfu Liang, Xuenuo Wu
KEYWORDS:
Heart Failure, Anxiety, Depression, Sacubitril Valsartan, Zhenyuan Capsule, Inflammatory Factors
JOURNAL NAME:
Natural Science,
Vol.14 No.6,
June
24,
2022
ABSTRACT: Objective: To investigate the effect of sacubitril-valsartan combined with Zhenyuan capsule in the treatment of chronic heart failure comorbid anxiety and depression and its effect on the level of inflammatory factors. Methods: A total of 106 patients with chronic heart failure comorbid anxiety and depression from February 2020 to March 2022 were continuously enrolled and divided into control group (36 cases), observation group A (36 cases) and observation group B (34 cases) according to treatment methods. All groups were given conventional treatment. On the basis of routine treatment, the control group, observation group A and observation group B were given valsartan, sacubitril-valsartan and sacubitril-valsartan plus Zhenyuan Capsules for the treatment of consecutive 8 weeks. The patients in the 3 groups were evaluated by the Self-rating Anxiety Scale (SAS) and Self-rating Depression Scale (SDS) before and after treatment, and the clinical efficacy of heart failure was evaluated, and the detection of left ventricular ejection fraction (LVEF), left ventricular end systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), N terminal brain natriuretic peptide (NT-proBNP), tumor necrosis factor alpha (TNF alpha), interleukin 6 (IL-6), c-reactive protein (CRP) was conducted. Results: The clinical efficacy rate and total effective rate of heart failure in observation group A and observation group B were significantly higher than those in the control group (P